{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/391940695"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "Prexa Pharmaceuticals is developing small molecules designed to enhance the action of the neurotransmitter dopamine, potentially providing new alternatives to treating CNS diseases and disorders such as ADHD, depression, and Parkinson??s disease." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "prexainc.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/7782209"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/391940695" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/454778640"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/391940695"] } } }
